Volition RX – our joint journey towards better cancer prevention continues
Our journey with client, Volition RX, who are developing a simple, cost effective and highly accurate test for various cancers, has continued with a special video report with the organisation’s Scientific Advisory Board (SAB).
The video was recorded on our recent visit to the company’s main European facility in Namur, Belgium, where the SAB were holding a meeting.
To see the video report in full, click here
Members of Volition’s SAB pictured outside the company’s facility in Namur, Belgium
Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
The SAB is a multi-disciplinary international board with expertise in broad areas of technology and convenes at least twice a year to give high level advice and counsel to Volition’s scientific team. Chaired by Dr. Alan Colman, the Board has seven other members, all highly-respected leading experts in their individual fields. The team meets in Namur which was set up by Volition as their central facility for testing blood samples from their various trials that are taking place around the world currently.
Dr. Colman commented “The role of the SAB is to review and advise the Volition team on the development of its scientific program. Every member provides invaluable insight and input which helps drive scientific rigour.”
As cancer screening programs become more widespread, Volition’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition RX will be in California for this event in 2019
Volition intends to expand the application of its technology beyond cancer by exploring other disease applications. The company’s research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as it focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
Watch out for a video invitation to meet with Volition RX during the forthcoming 36th J.P. Morgan Annual Healthcare Conference being held in San Francisco between January 8-11, 2019 which we will be recording and publishing shortly.
